Cancer News: Neuroendocrine

Positive results of everolimus in neuroendocrine tumors

Everolimus increased median progression-free survival in patients with neuroendocrine tumors of the gastrointestinal tract or unknown origin.

Neuroendocrine tumors responded to new chemotherapy combination in trial

Promising interim results of a new chemotherapy combination against with advanced neuroendocrine tumors show promise during a trial, for 95% of patient group.